We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+15.22%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$280M
AUM Growth
+$4.87M
Cap. Flow
-$17.4M
Cap. Flow %
-6.19%
Top 10 Hldgs %
28.7%
Holding
166
New
40
Increased
28
Reduced
35
Closed
35

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$5.21M
2
ANSS
Ansys
ANSS
+$4.33M
3
JNPR
Juniper Networks
JNPR
+$4.19M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$2.49M
5
SWTX
SpringWorks Therapeutics
SWTX
+$2.36M

Top Sells

Rank Stock Value
1
SYRE icon
Spyre Therapeutics
SYRE
+$12.3M
2
IMVT icon
Immunovant
IMVT
+$5.11M
3
IMGN
Immunogen Inc
IMGN
+$4.29M
4
SPLK
Splunk Inc
SPLK
+$4.2M
5
SOVO
Sovos Brands, Inc. Common Stock
SOVO
+$4.07M

Sector Composition

Rank Sector Weight
1 Healthcare 44.78%
2 Technology 11.84%
3 Consumer Discretionary 7.8%
4 Industrials 6.17%
5 Financials 4.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
101
Abivax
ABVX
$11.1B
$826K 0.29%
+57,762
New +$745K
GERN icon
102
Geron
GERN
$1.05B
$793K 0.28%
240,234
– –
RPTX
103
DELISTED
Repare Therapeutics
RPTX
$778K 0.28%
165,173
– –
CRNX icon
104
Crinetics Pharmaceuticals
CRNX
$8.95B
$744K 0.27%
15,899
– –
IMRX icon
105
Immuneering
IMRX
$311M
$736K 0.26%
254,513
– –
KRYS icon
106
Krystal Biotech
KRYS
$9.68B
$698K 0.25%
+3,923
New +$545K
ASND icon
107
Ascendis Pharma A/S
ASND
$16.7B
$684K 0.24%
4,527
+1,699
+60% +$242K
MDGL icon
108
Madrigal Pharmaceuticals
MDGL
$12.4B
$677K 0.24%
2,534
+1,103
+77% +$260K
PCVX icon
109
Vaxcyte
PCVX
$8.81B
$637K 0.23%
9,321
– –
RYTM icon
110
Rhythm Pharmaceuticals
RYTM
$7.77B
$622K 0.22%
14,362
– –
PTGX icon
111
Protagonist Therapeutics
PTGX
$9.6B
$614K 0.22%
21,229
-7,130
-25% -$194K
BEKE icon
112
KE Holdings
BEKE
$18.7B
$588K 0.21%
42,807
-11,300
-21% -$158K
BIDU icon
113
Baidu
BIDU
$35.9B
$578K 0.21%
5,486
-1,400
-20% -$149K
TCOM icon
114
Trip.com Group
TCOM
$29.1B
$554K 0.2%
12,629
-11,500
-48% -$467K
MRSN
115
DELISTED
Mersana Therapeutics
MRSN
$548K 0.2%
+4,893
New +$486K
VRNA
116
DELISTED
Verona Pharma
VRNA
$522K 0.19%
32,449
– –
SNDX icon
117
Syndax Pharmaceuticals
SNDX
$1.81B
$512K 0.18%
+21,519
New +$480K
MIRM icon
118
Mirum Pharmaceuticals
MIRM
$5.99B
$508K 0.18%
+20,208
New +$556K
PLRX icon
119
Pliant Therapeutics
PLRX
$63.8M
$507K 0.18%
34,039
– –
TSVT
120
DELISTED
2seventy bio
TSVT
$500K 0.18%
+93,500
New +$440K
FDMT icon
121
4D Molecular Therapeutics
FDMT
$600M
$495K 0.18%
15,532
-24,810
-61% -$633K
RVMD icon
122
Revolution Medicines
RVMD
$44.1B
$462K 0.16%
14,325
-8,325
-37% -$247K
SLNO
123
DELISTED
Soleno Therapeutics
SLNO
$446K 0.16%
+10,428
New +$472K
APLS
124
DELISTED
Apellis Pharmaceuticals
APLS
$427K 0.15%
+7,266
New +$463K
EDU icon
125
New Oriental
EDU
$8.84B
$408K 0.15%
4,700
-2,400
-34% -$204K
3 4
5
6 7

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
PPG
Peak Planning Group Centennial, Colorado $361M AUM 22.01% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

HighVista Strategies's Q1 2024 Portfolio in Review

As of Q1 2024, HighVista Strategies held 166 positions worth $280M, up 1.8% from $276M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

HighVista Strategies withdrew a net $17.4M in Q1 2024, closing 35 positions and reducing 35 holdings. Its most notable exit was Immunovant, an estimated $5.11M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, HighVista Strategies opened a new position in Apogee Therapeutics worth $7.93M.

  • HighVista Strategies's largest Q1 2024 buy was Apogee Therapeutics: 119,403 shares worth $7.93M.
  • HighVista Strategies added most to argenx in Q1 2024, an estimated $2.2M increase.
  • HighVista Strategies's biggest Q1 2024 reduction was Spyre Therapeutics, cutting an estimated $12.3M.
  • HighVista Strategies fully exited Immunovant in Q1 2024, selling an estimated $5.11M.
  • HighVista Strategies's ten largest holdings make up 29% of its $280M portfolio in Q1 2024.
  • HighVista Strategies opened 40 new positions and closed 35 in Q1 2024.
  • HighVista Strategies's portfolio value rose 1.8% quarter-over-quarter to $280M.

Based on HighVista Strategies's 13F filing for Q1 2024, filed 15 May 2024.